{"id":380551,"date":"2020-11-12T20:04:12","date_gmt":"2020-11-13T01:04:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380551"},"modified":"2020-11-12T20:04:12","modified_gmt":"2020-11-13T01:04:12","slug":"odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/","title":{"rendered":"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action &#8211; ODT"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">Nov. 12, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between <span class=\"xn-chron\">December 7, 2017<\/span> and <span class=\"xn-chron\">August 21, 2020<\/span>, inclusive (the &#8220;Class Period&#8221;), of the important <span class=\"xn-chron\">November 16, 2020<\/span> lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Odonate investors under the federal securities laws.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg\" title=\"Rosen Law Firm, P.A. Logo\" alt=\"Rosen Law Firm, P.A. Logo\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>To join the Odonate class action, go to <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2980788-1&amp;h=3935486440&amp;u=http%3A%2F%2Fwww.rosenlegal.com%2Fcases-register-1946.html&amp;a=http%3A%2F%2Fwww.rosenlegal.com%2Fcases-register-1946.html\" rel=\"nofollow noopener noreferrer\">http:\/\/www.rosenlegal.com\/cases-register-1946.html<\/a> or call <span class=\"xn-person\">Phillip Kim, Esq.<\/span> toll-free at 866-767-3653 or email <a target=\"_blank\" href=\"mailto:pkim@rosenlegal.com\" rel=\"nofollow noopener noreferrer\">pkim@rosenlegal.com<\/a> or <a target=\"_blank\" href=\"mailto:cases@rosenlegal.com\" rel=\"nofollow noopener noreferrer\">cases@rosenlegal.com<\/a> for information on the class action. <\/p>\n<p>According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose to investors that: (1) tesetaxel was not as safe or well-tolerated as Odonate had led investors to believe; (2) consequently, tesetaxel&#8217;s commercial viability as a cancer treatment was overstated; and (3) as a result, defendants&#8217; public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n<p>A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court <b>no later than <span class=\"xn-chron\">November 16, 2020<\/span><\/b>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2980788-1&amp;h=3935486440&amp;u=http%3A%2F%2Fwww.rosenlegal.com%2Fcases-register-1946.html&amp;a=http%3A%2F%2Fwww.rosenlegal.com%2Fcases-register-1946.html\" rel=\"nofollow noopener noreferrer\">http:\/\/www.rosenlegal.com\/cases-register-1946.html<\/a> or to discuss your rights or interests regarding this class action, please contact <span class=\"xn-person\">Phillip Kim, Esq.<\/span> of Rosen Law Firm toll free at 866-767-3653 or via e-mail at <a target=\"_blank\" href=\"mailto:pkim@rosenlegal.com\" rel=\"nofollow noopener noreferrer\">pkim@rosenlegal.com<\/a> or <a target=\"_blank\" href=\"mailto:cases@rosenlegal.com\" rel=\"nofollow noopener noreferrer\">cases@rosenlegal.com<\/a>.<\/p>\n<p>NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR&#8217;S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.<\/p>\n<p>Follow us for updates on LinkedIn: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2980788-1&amp;h=35580745&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm\" rel=\"nofollow noopener noreferrer\">https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2980788-1&amp;h=947560733&amp;u=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;a=https%3A%2F%2Ftwitter.com%2Frosen_firm\" rel=\"nofollow noopener noreferrer\">https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2980788-1&amp;h=3360139312&amp;u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&amp;a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F\" rel=\"nofollow noopener noreferrer\">https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>. <\/p>\n<p>Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm&#8217;s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n<p>Contact Information:<\/p>\n<p id=\"indentid\" class=\"prnml40\">\n        <span class=\"xn-person\">Laurence Rosen, Esq.<\/span><br \/>\n        <br \/>\n        <span class=\"xn-person\">Phillip Kim, Esq.<\/span><br \/>\n        <br \/>The Rosen Law Firm, P.A.<br \/>275 Madison Avenue, 40th Floor<br \/><span class=\"xn-location\">New York, NY<\/span> 10016<br \/>Tel: (212) 686-1060<br \/>Toll Free: (866) 767-3653<br \/>Fax: (212) 202-3827<br \/><a target=\"_blank\" href=\"mailto:lrosen@rosenlegal.com\" rel=\"nofollow noopener noreferrer\">lrosen@rosenlegal.com<\/a><br \/><a target=\"_blank\" href=\"mailto:pkim@rosenlegal.com\" rel=\"nofollow noopener noreferrer\">pkim@rosenlegal.com<\/a><br \/><a target=\"_blank\" href=\"mailto:cases@rosenlegal.com\" rel=\"nofollow noopener noreferrer\">cases@rosenlegal.com<\/a><br \/><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2980788-1&amp;h=1436468945&amp;u=http%3A%2F%2Fwww.rosenlegal.com%2F&amp;a=www.rosenlegal.com\" rel=\"nofollow noopener noreferrer\">www.rosenlegal.com<\/a><\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC90723&amp;sd=2020-11-12\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action--odt-301172467.html\">http:\/\/www.prnewswire.com\/news-releases\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action&#8211;odt-301172467.html<\/a><\/p>\n<p>SOURCE  Rosen Law Firm, P.A.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC90723&amp;Transmission_Id=202011122001PR_NEWS_USPR_____DC90723&amp;DateId=20201112\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, Nov. 12, 2020 \/PRNewswire\/ &#8212;\u00a0Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the &#8220;Class Period&#8221;), of the important November 16, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Odonate investors under the federal securities laws. To join the Odonate class action, go to http:\/\/www.rosenlegal.com\/cases-register-1946.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose to investors that: (1) tesetaxel was &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action &#8211; ODT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380551","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Nov. 12, 2020 \/PRNewswire\/ &#8212;\u00a0Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the &#8220;Class Period&#8221;), of the important November 16, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Odonate investors under the federal securities laws. To join the Odonate class action, go to http:\/\/www.rosenlegal.com\/cases-register-1946.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose to investors that: (1) tesetaxel was &hellip; Continue reading &quot;ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action &#8211; ODT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T01:04:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action &#8211; ODT\",\"datePublished\":\"2020-11-13T01:04:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/\"},\"wordCount\":544,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/\",\"name\":\"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"datePublished\":\"2020-11-13T01:04:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action &#8211; ODT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/","og_locale":"en_US","og_type":"article","og_title":"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT - Market Newsdesk","og_description":"PR Newswire NEW YORK, Nov. 12, 2020 \/PRNewswire\/ &#8212;\u00a0Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the &#8220;Class Period&#8221;), of the important November 16, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Odonate investors under the federal securities laws. To join the Odonate class action, go to http:\/\/www.rosenlegal.com\/cases-register-1946.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose to investors that: (1) tesetaxel was &hellip; Continue reading \"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action &#8211; ODT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T01:04:12+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action &#8211; ODT","datePublished":"2020-11-13T01:04:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/"},"wordCount":544,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/","name":"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","datePublished":"2020-11-13T01:04:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odt-final-deadline-rosen-leading-investor-counsel-reminds-odonate-therapeutics-inc-investors-of-important-monday-deadline-in-securities-class-action-odt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action &#8211; ODT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380551"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380551\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}